Literature DB >> 26419450

Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.

Boyoon Choi1, Myeong Gyu Kim1, Nayoung Han1, Therasa Kim2, Eunhee Ji3, Seonyang Park4, In-Wha Kim1, Jung Mi Oh1.   

Abstract

AIM: A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS &
METHODS: A PPK model was developed from 36 patients by a one-compartment model with first-order elimination.
RESULTS: The typical value of clearance and volume of distribution were 11.0 l/h and 42.4 l, respectively. Clearance decreased by 15% and area under the concentration-time curves (AUCs) increased with GSTA1 variants compared with wild-type (both p < 0.05). Subtherapeutic AUCs were seen only in wild-type patients.
CONCLUSION: To our knowledge, this is the first PPK study to suggest that GSTA1 polymorphisms in adults are associated with busulfan PK.

Entities:  

Keywords:  GSTA1; alloHSCT; allogeneic hematopoietic stem cell transplantation; busulfan; clinical outcomes; genetic polymorphisms; glutathione s-transferase a1; population pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 26419450     DOI: 10.2217/pgs.15.98

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  14 in total

1.  Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.

Authors:  Tiago Nava; Nastya Kassir; Mohamed Aziz Rezgui; Chakradhara Rao Satyanarayana Uppugunduri; Patricia Huezo-Diaz Curtis; Michel Duval; Yves Théoret; Liane E Daudt; Catherine Litalien; Marc Ansari; Maja Krajinovic; Henrique Bittencourt
Journal:  Br J Clin Pharmacol       Date:  2018-04-27       Impact factor: 4.335

2.  Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Adrin Dadkhah; Sebastian Georg Wicha; Nicolaus Kröger; Alexander Müller; Christoph Pfaffendorf; Maria Riedner; Anita Badbaran; Boris Fehse; Claudia Langebrake
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

3.  Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.

Authors:  Yidan Sun; Jingjing Huang; Chenxia Hao; Ziwei Li; Wu Liang; Weixia Zhang; Bing Chen; Wanhua Yang; Jiong Hu
Journal:  Cancer Chemother Pharmacol       Date:  2019-12-13       Impact factor: 3.333

4.  GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.

Authors:  Marc Ansari; Patricia Huezo-Diaz Curtis; Chakradhara Rao S Uppugunduri; Mohammed Aziz Rezgui; Tiago Nava; Vid Mlakar; Laurence Lesne; Yves Théoret; Yves Chalandon; Lee L Dupuis; Tao Schechter; Imke H Bartelink; Jaap J Boelens; Robbert Bredius; Jean-Hugues Dalle; Saba Azarnoush; Petr Sedlacek; Victor Lewis; Martin Champagne; Christina Peters; Henrique Bittencourt; Maja Krajinovic
Journal:  Oncotarget       Date:  2017-08-27

Review 5.  Glutathione S-transferase π: a potential role in antitumor therapy.

Authors:  Shu-Chen Dong; Huan-Huan Sha; Xiao-Yue Xu; Tian-Mu Hu; Rui Lou; Huizi Li; Jian-Zhong Wu; Chen Dan; Jifeng Feng
Journal:  Drug Des Devel Ther       Date:  2018-10-23       Impact factor: 4.162

6.  Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Veronique Michaud; My Tran; Benoit Pronovost; Philippe Bouchard; Sarah Bilodeau; Karine Alain; Barbara Vadnais; Martin Franco; François Bélanger; Jacques Turgeon
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

7.  The analysis of GSTA1 promoter genetic and functional diversity of human populations.

Authors:  Tiago Nava; Marc Ansari; Vid Mlakar; Patricia Huezo-Diaz Curtis; Marc Armengol; Victor Ythier; Isabelle Dupanloup; Khalil Ben Hassine; Laurence Lesne; Rabih Murr; Simona Jurkovic Mlakar
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

8.  Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation.

Authors:  Adrin Dadkhah; Dzenefa Alihodzic; Astrid Broeker; Nicolaus Kröger; Claudia Langebrake; Sebastian G Wicha
Journal:  Pharm Res       Date:  2021-10-18       Impact factor: 4.200

9.  Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations.

Authors:  Jinjie Yuan; Ning Sun; Xinying Feng; Huan He; Dong Mei; Guanghua Zhu; Libo Zhao
Journal:  Pharmgenomics Pers Med       Date:  2021-02-15

10.  A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance.

Authors:  Jurgen B Langenhorst; Jill Boss; Charlotte van Kesteren; Arief Lalmohamed; Jürgen Kuball; Antoine C G Egberts; Jaap Jan Boelens; Alwin D R Huitema; Erik M van Maarseveen
Journal:  Br J Clin Pharmacol       Date:  2020-03-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.